Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease

Clinical Biochemistry

Volumn 35, Issue 3, 2002, Pages 197-203

  Ferre, Natalia ^a   Tous, Monica ^a   Paul, Antoni ^a   Zamora, Alberto ^b   Vendrell, J ^b   Bardají, Alfredo ^b   Camps, Jordi ^a   Richart, Cristobal ^b   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Lipids; Mediterranean diet; Myocardial infarction; Oxidation; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ESTERASE; PON1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; AMINO ACID SUBSTITUTION; CHEMISTRY; CORONARY ARTERY DISEASE; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HEART INFARCTION; METABOLISM; MIDDLE AGED; RISK; RISK FACTOR;

AGED; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; ESTERASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0036017351     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00295-3     Document Type: Article

References (52)

1. Lipoprotein oxidation in dyslipidemia: Insights into general mechanisms affecting lipoprotein oxidative behaviour
2. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
3. Antioxidative activity of high density lipoproteins in vivo
4. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
5. Protective effect of high density lipoprotein associated paraoxonase
6. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions
7. Paraoxonase and atherosclerosis
8. The human serum paraoxonase/arylesterase polymorphism
9. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme
10. Two alleles of the human paraoxonase gene produce different amounts of mRNA
11. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
12. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
13. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
14. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type2 diabetes
15. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus
16. A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
17. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus
18. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
19. The Gln-Arg192 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
20. Lack of association between carotid intima-media thickness and paraoxonase polymorphism in non-insulin dependent diabetes mellitus
21. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease
22. Influence of the human paraoxonase polymorphism (PON1 192) on the carotid-wall thickening in a healthy population
23. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
24. The Met54Leu polymorphism of paraoxonase (PON) enzyme gene is not a genetic risk factor for non-insulin-dependent diabetes mellitus in Finns
25. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
26. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese
27. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
28. Genetic variations of the paraoxonase gene in patients with coronary artery disease
29. 55 genotype
30. Myocardial infarction and coronary deaths in the World Health Organization MONICA project
31. Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction
32. Report of the Joint International Society, and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature: Nomenclature and criteria for diagnosis of ischemic heart disease
33. The molecular basis of the serum paraoxonase activity polymorphism
34. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure
35. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis
36. Agreement study of methods based on the elimination principle for the measurement of LDL- and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis
37. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
38. Genetic dissection of complex traits
39. The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors
40. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease
41. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
42. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities
43. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism
44. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin
45. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
46. The antioxidant potential of the Mediterranean diet
47. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat
48. Daily moderate alcohol consumption increases serum paraoxonase activity: A diet-controlled, randomised intervention study in middle-aged men
49. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
50. Reduced progression of atherosclerosis in apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation
51. Does paraoxonase play a role in susceptibility to cardiovascular disease?
52. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations